Clene Reports Full Year 2023 Financial Results and Recent Op

Initiated discussions with FDA regarding accelerated approval pathway for CNM-Au8® for the treatment of ALS with the objective of submitting an NDA in 2024Released long-term data from the open-label extension

Related Keywords

National Institutes Of Health , Maryland , United States , Utah , Salt Lake City , Rob Etherington , Clene Nanomedicine , Clene Inc , Access Program , Natural History Consortium , Securities Exchange , Linkedin , National Institute Of Neurological Disorders , Twitter , University Of South Carolina , Clene Nanomedicine Inc , Columbia University , Drug Administration , Nasdaq , Expanded Access Program , Recent Operating , National Institute , Neurological Disorders , National Institutes , History Consortium , Brain Target Engagement , Multiple Sclerosis , Investigational Nanomedicine , Springer Nature , Mechanism Underpinning , Bioenergetic Metabolism Regulating Function , Gold Nanocatalysts , South Carolina , Open Access , Securities Exchange Act , Securities Act , Annual Report , Quarterly Reports , Ended December , Initial Stockholders , Region ,